Teva TEVA says, "Cephalon CEPH enterprise value includes conversion of convertibles... Cephalon is `great strategic fit'... sees $500M of cost savings from Cephalon purchase... sees cost savings in third year after closing... expects to have $1 billion in cash after closing... will have debt-ebitda ratio of 2 after closing... will have financial flexibility afer Cephalon purchase... purchase values Cephalon generic risk appropriately."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in